CA2468082C - Assay for screening candidate drugs for the treatment of inflammatory diseases - Google Patents
Assay for screening candidate drugs for the treatment of inflammatory diseases Download PDFInfo
- Publication number
- CA2468082C CA2468082C CA2468082A CA2468082A CA2468082C CA 2468082 C CA2468082 C CA 2468082C CA 2468082 A CA2468082 A CA 2468082A CA 2468082 A CA2468082 A CA 2468082A CA 2468082 C CA2468082 C CA 2468082C
- Authority
- CA
- Canada
- Prior art keywords
- thetaiotaomicron
- cells
- enteritidis
- inflammatory
- ppary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0127916.5 | 2001-11-21 | ||
| GBGB0127916.5A GB0127916D0 (en) | 2001-11-21 | 2001-11-21 | Method |
| PCT/GB2002/005255 WO2003046580A1 (en) | 2001-11-21 | 2002-11-20 | Assay for screening candidate drugs for the treatment of inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2468082A1 CA2468082A1 (en) | 2003-06-05 |
| CA2468082C true CA2468082C (en) | 2012-06-26 |
Family
ID=9926193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2468082A Expired - Lifetime CA2468082C (en) | 2001-11-21 | 2002-11-20 | Assay for screening candidate drugs for the treatment of inflammatory diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7998474B2 (https=) |
| EP (1) | EP1448995B9 (https=) |
| JP (2) | JP5362940B2 (https=) |
| AT (1) | ATE496302T1 (https=) |
| AU (1) | AU2002343063B2 (https=) |
| CA (1) | CA2468082C (https=) |
| DE (1) | DE60239009D1 (https=) |
| DK (1) | DK1448995T3 (https=) |
| ES (1) | ES2362494T3 (https=) |
| GB (1) | GB0127916D0 (https=) |
| WO (1) | WO2003046580A1 (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050390A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2211879B1 (en) * | 2007-10-26 | 2014-05-07 | Brenda E. Moore | Probiotic compositions and methods for inducing and supporting weight loss |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| WO2010091894A2 (en) | 2009-02-16 | 2010-08-19 | Giuliani International Limited | Methods of treating hair related conditions |
| WO2012097207A2 (en) * | 2011-01-13 | 2012-07-19 | The Johns Hopkins University | Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| US20130022575A1 (en) * | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
| GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN103857402A (zh) | 2011-10-11 | 2014-06-11 | 阿基姆医药公司 | 包括厌氧培养的人类肠道微生物群的组合物 |
| CN109999017A (zh) | 2012-02-09 | 2019-07-12 | 诺格拉制药有限公司 | 治疗纤维化的方法 |
| CA3008794C (en) | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| CN104284655B (zh) | 2012-04-18 | 2017-10-27 | 诺格拉制药有限公司 | 治疗乳糖不耐受的方法 |
| WO2013188529A1 (en) | 2012-06-15 | 2013-12-19 | Temple University Of The Commonwealth System Of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN104546935A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| AR103260A1 (es) * | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| AU2018205072B2 (en) * | 2014-12-23 | 2020-05-21 | Cj Bioscience, Inc. | Immune modulation |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| FR3035329A1 (fr) * | 2015-04-23 | 2016-10-28 | Agronomique Inst Nat Rech | La prevention ou le traitement d'une infection par bacteroides thetaiotaomicron |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| WO2017029992A1 (ja) * | 2015-08-17 | 2017-02-23 | 積水メディカル株式会社 | 免疫学的検出方法及びこれに用いるテストストリップ |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN108513545B (zh) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| ME03487B (me) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI750342B (zh) * | 2016-06-15 | 2021-12-21 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI621708B (zh) * | 2016-06-15 | 2018-04-21 | ４Ｄ製藥研究有限公司 | 免疫調節 |
| TWI782800B (zh) * | 2016-06-15 | 2022-11-01 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| JP2021516216A (ja) | 2018-01-19 | 2021-07-01 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| BR112020014565A2 (pt) | 2018-01-19 | 2020-12-08 | 4D Pharma Research Limited | Terapia de combinação para tratamento ou prevenção de câncer |
| MX2020007665A (es) | 2018-01-19 | 2020-09-14 | 4D Pharma Res Limited | Terapia de combinacion para tratar o prevenir el cancer. |
| JP2021510688A (ja) | 2018-01-19 | 2021-04-30 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| WO2019180051A1 (en) | 2018-03-19 | 2019-09-26 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PL3743086T3 (pl) | 2018-05-11 | 2022-06-20 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| SG11202010958YA (en) | 2018-06-14 | 2020-12-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| SG11202012621VA (en) | 2018-06-19 | 2021-01-28 | 4D Pharma Res Ltd | Dosage form comprising a live biotherapeutic product |
| SI3723777T1 (sl) | 2018-06-25 | 2021-08-31 | 4D Pharma Research Limited | Sestave, ki zajemajo bakterijske seve |
| SG11202100228XA (en) | 2018-07-16 | 2021-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| TW202023590A (zh) | 2018-08-17 | 2020-07-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| US12144834B2 (en) | 2018-09-13 | 2024-11-19 | Xbiome Inc. | Methods and compositions for treating gastrointestinal and inflammatory disorders |
| EP3852775A1 (en) | 2018-09-20 | 2021-07-28 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EA202190876A1 (ru) * | 2018-10-09 | 2021-07-02 | 4Д Фарма Рисерч Лимитед | Композиции, содержащие бактериальные штаммы |
| WO2020079282A1 (en) | 2018-10-19 | 2020-04-23 | 4D Pharma Research Ltd | Compositions comprising bacterial strains |
| WO2020089488A1 (en) | 2018-11-02 | 2020-05-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202038979A (zh) | 2018-12-12 | 2020-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| SG11202106258YA (en) | 2018-12-12 | 2021-07-29 | 4D Pharma Res Ltd | Compositions comprising parabacteroides bacterial strains for treating cancer |
| JP2022511975A (ja) | 2018-12-12 | 2022-02-01 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| EP4495101A3 (en) | 2019-02-08 | 2025-04-30 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| MX2021013776A (es) | 2019-05-10 | 2021-12-10 | 4D Pharma Res Limited | Composiciones que comprenden cepas bacterianas. |
| CA3145904A1 (en) | 2019-07-05 | 2021-01-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP4061389A1 (en) | 2019-11-20 | 2022-09-28 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP3839039A1 (en) | 2019-12-16 | 2021-06-23 | 4D Pharma Research Limited | Providing bacterial biomass with improved storage stability |
| EP3838281A1 (en) | 2019-12-20 | 2021-06-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202140773A (zh) | 2020-01-27 | 2021-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| TW202220639A (zh) | 2020-08-06 | 2022-06-01 | 英商４Ｄ製藥有限公司 | 凍乾方法 |
| TW202225403A (zh) | 2020-11-26 | 2022-07-01 | 西班牙商４Ｄ製藥雷昂有限責任公司 | 方法 |
| US20240148799A1 (en) * | 2021-03-08 | 2024-05-09 | Juntendo Educational Foundation | Composition and ameliorating agent having inflammation reducing effect |
| JP2024540522A (ja) * | 2021-11-19 | 2024-10-31 | ザ・ブロード・インスティテュート・インコーポレイテッド | キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| DE68928665T2 (de) | 1988-08-02 | 1998-11-12 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
| US5039703A (en) * | 1989-11-16 | 1991-08-13 | Breuer Richard I | Method for treating inflammatory bowel disorders |
| US5599795A (en) * | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| GB9616047D0 (en) | 1996-07-31 | 1996-09-11 | Glaxo Group Ltd | Medicament carrier with agglomerated large medicament particles and related method of manufacture thereof |
| AU6773598A (en) | 1997-03-26 | 1998-10-20 | Institut Pasteur | Treatment of gastrointestinal disease with ppar modulators |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US5951977A (en) * | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20040062757A1 (en) * | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| JP2004528329A (ja) * | 2001-04-18 | 2004-09-16 | メルク エンド カムパニー インコーポレーテッド | 炎症を処置するためのＰＰＡＲα〜γのリガンドまたはアゴニスト |
-
2001
- 2001-11-21 GB GBGB0127916.5A patent/GB0127916D0/en not_active Ceased
-
2002
- 2002-10-31 US US10/285,224 patent/US7998474B2/en not_active Expired - Fee Related
- 2002-11-20 CA CA2468082A patent/CA2468082C/en not_active Expired - Lifetime
- 2002-11-20 AU AU2002343063A patent/AU2002343063B2/en not_active Expired
- 2002-11-20 EP EP02779724A patent/EP1448995B9/en not_active Expired - Lifetime
- 2002-11-20 AT AT02779724T patent/ATE496302T1/de not_active IP Right Cessation
- 2002-11-20 DE DE60239009T patent/DE60239009D1/de not_active Expired - Lifetime
- 2002-11-20 JP JP2003547968A patent/JP5362940B2/ja not_active Expired - Fee Related
- 2002-11-20 ES ES02779724T patent/ES2362494T3/es not_active Expired - Lifetime
- 2002-11-20 WO PCT/GB2002/005255 patent/WO2003046580A1/en not_active Ceased
- 2002-11-20 DK DK02779724.0T patent/DK1448995T3/da active
-
2012
- 2012-09-06 JP JP2012196103A patent/JP2013046615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002343063A1 (en) | 2003-06-10 |
| ATE496302T1 (de) | 2011-02-15 |
| EP1448995B9 (en) | 2011-10-12 |
| GB0127916D0 (en) | 2002-01-16 |
| EP1448995A1 (en) | 2004-08-25 |
| US20030133875A1 (en) | 2003-07-17 |
| WO2003046580A1 (en) | 2003-06-05 |
| DK1448995T3 (da) | 2011-05-16 |
| DE60239009D1 (de) | 2011-03-03 |
| AU2002343063B2 (en) | 2008-06-05 |
| CA2468082A1 (en) | 2003-06-05 |
| JP2013046615A (ja) | 2013-03-07 |
| ES2362494T3 (es) | 2012-10-05 |
| JP5362940B2 (ja) | 2013-12-11 |
| US7998474B2 (en) | 2011-08-16 |
| JP2005510733A (ja) | 2005-04-21 |
| EP1448995B1 (en) | 2011-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2468082C (en) | Assay for screening candidate drugs for the treatment of inflammatory diseases | |
| Engevik et al. | Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways | |
| Covasa et al. | Intestinal sensing by gut microbiota: targeting gut peptides | |
| Virili et al. | Gut microbiome and thyroid autoimmunity | |
| Benyacoub et al. | Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in mice | |
| Lu et al. | Lactic acid bacteria isolated from Korean kimchi activate the vitamin D receptor–autophagy signaling pathways | |
| Li et al. | Risks associated with high-dose Lactobacillus rhamnosus in an Escherichia coli model of piglet diarrhoea: intestinal microbiota and immune imbalances | |
| Hannan et al. | Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection | |
| Reichold et al. | Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model | |
| Van Der Kleij et al. | Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve | |
| Savkovic et al. | EPEC-activated ERK1/2 participate in inflammatory response but not tight junction barrier disruption | |
| Moratalla et al. | Protective effect of Bifidobacterium pseudocatenulatum CECT 7765 against induced bacterial antigen translocation in experimental cirrhosis | |
| CN105008924B9 (zh) | 用于治疗和/或预防腹泻的益生菌菌株 | |
| Mellits et al. | Activation of the transcription factor NF-κB by Campylobacter jejuni | |
| Chang et al. | Glucagon‐like peptide 2 attenuates intestinal mucosal barrier injury through the MLCK/pMLC signaling pathway in a piglet model | |
| Liu et al. | Dietary supplementation of n-3 LCPUFAs prevents salmonellosis in a murine model | |
| Lee et al. | Probiotic Limosilactobacillus reuteri (Lactobacillus reuteri) extends the lifespan of Drosophila melanogaster through insulin/IGF-1 signaling | |
| Gallois et al. | Maternal milk contains antimicrobial factors that protect young rabbits from enteropathogenic Escherichia coli infection | |
| WO2008124842A1 (en) | Treatments with helminths | |
| Choudhry et al. | Reversal of pathogen-induced barrier defects in intestinal epithelial cells by contra-pathogenicity agents | |
| Al-Salami et al. | Probiotics applications in autoimmune diseases | |
| Llorente et al. | IL6ST-induced muscarinic receptor opens goblet cell associated antigen passages to suppress alcoholic liver disease | |
| El-Deeb et al. | Probiotics and GIT diseases/stomach ulcer | |
| Karin et al. | IL6ST–induced muscarinic receptor opens goblet cell associated antigen passages to suppress alcoholic liver disease | |
| Ogbodo | Immunoregulatory properties of Helicobacter pylori derived molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221121 |